… a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab.
… , placebo-controlled, phase 3 trial, we compared evolocumab with placebo in patients with …

… for 52 weeks (Figure 1). Ninety-two percent of patients in the evolocumab+SOC group
completed 52 weeks of follow-up, and 89% of patients in the SOC group completed 52 weeks of …

… In this study, evolocumab was dosed at day 1, week 4 and week 8. Thus, week 12 was at the
end … In the BANTING trial, we observed that a substantially greater proportion of participants …

… This study overcomes the limitations of individual trials and demonstrates that evolocumab
has greater efficacy at 140 mg Q2W than at 420 mg Q4W in modulating LDL-C levels and …

… As expected, vitamin E levels changed similarly to lipids among patients treated for 52 weeks
with evolocumab. No adverse effects were observed in steroid or gonadal hormones, even …

… receive evolocumab plus standard of care (SOC) or SOC alone for the first 52 weeks during
… longest clinical trial exposure to a PCSK9 inhibitor to date, evolocumab produced sustained …

… parameters were balanced between the pooled evolocumab dosing group and placebo or
ezetimibe comparators across all 12‐week randomized trials that contributed to this analysis. …

… (DESCARTES) was a 52-week placebo-controlled trial of evolocumab that randomized
905 … duration of 52 weeks and the possibility that potential effects of evolocumab on insulin …

… lipids in patients treated for 52 weeks with evolocumab (Table 2). At week 52, average LDL-C
… trial demonstrates that evolocumab induces marked reductions in LDL-C and LDL-P after …

Introduction: Evolocumab (AMG 145), a fully human monoclonal antibody to proprotein
convertase subtilisin-kexin type 9 (PCSK9), can reduce LDL-C to very low levels, particularly …